Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Common Equity (2017 - 2025)

Historic Common Equity for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Common Equity rose 2871.49% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2871.49%. This contributed to the annual value of $1.3 billion for FY2024, which is 14574.11% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Common Equity stood at $1.1 billion for Q3 2025, which was up 2871.49% from $1.2 billion recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Common Equity's 5-year high stood at $1.3 billion during Q4 2024, with a 5-year trough of $149.5 million in Q1 2021.
  • Its 5-year average for Common Equity is $590.3 million, with a median of $386.2 million in 2022.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Common Equity tumbled by 3419.5% in 2023 and then skyrocketed by 22692.27% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Common Equity (Quarter) stood at $331.9 million in 2021, then decreased by 4.7% to $316.3 million in 2022, then surged by 70.43% to $539.1 million in 2023, then soared by 145.74% to $1.3 billion in 2024, then decreased by 19.07% to $1.1 billion in 2025.
  • Its Common Equity stands at $1.1 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.3 billion for Q1 2025.